Emerging data suggest a possible genetic contributor to CIDP. In a recent study, patients with CIDP had a high frequency of perforin gene variations that impair the function of cytotoxic T and ...

The diagnosis of CIDP is suspected with a history of progressive sensorimotor neuropathy. Physical examination consistent with distal sensory loss in the upper and lower extremities, in conjunction ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...

The MHLW approval is based on the ADHERE Study, the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with Vyvdura, regardless of prior treatment, ...

Clinical trials generally proceed through preclinical ... targeting chronic inflammatory demyelinating polyneuropathy (CIDP), within the first quarter of this year. On the first day of the ...

Financial writer covers success of Efgartigimod in myositis trials, company's strong revenue and cash position, and future ...

Kain Science passes technical evaluation for KOSDAQ special listing Kain Science moves closer to KOSDAQ listing after ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...